Pharmaceutical and biotechnology company Moderna has said preliminary results from its study on a COVID-19 vaccine intended to protect against variants of the virus show that it outperformed its currently authorized booster shot, mRNA-1273.
The company announced on April 19 that its first bivalent booster vaccine candidate, mRNA-1273.211—which includes mutations found in the Beta variant of concern—demonstrated “superiority” against the Beta, Delta, and Omicron variants of COVID-19 one month after being administered, compared to the booster shot of its original vaccine currently in use.
